<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31033">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02702713</url>
  </required_header>
  <id_info>
    <org_study_id>147/2015/U/Sper</org_study_id>
    <nct_id>NCT02702713</nct_id>
  </id_info>
  <brief_title>Pivotal Assessment of the Effects of Bioactive on Health and Wellbeing. From Human Genome to Food Industry</brief_title>
  <acronym>PATHWAY-27</acronym>
  <official_title>Investigation of the Effect of Daily Consumption of Bioactive Enriched Foods (BEF) on Biochemical and Anthropometric Markers of Metabolic Syndrome (MS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Max Rubner-Institut</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Recherche en Nutrition Humaine d'Auvergne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bologna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, randomised, double-blind, placebo-controlled, parallel-arm dietary
      intervention study. In total, 800 men and women at risk for Metabolic Syndrome (MS) will be
      recruited. Subjects will be eligible to the study if they present with two to four of the MS
      diagnostic criteria, at least one of them being:

        -  fasting triglycerides ≥150 mg/dL but ≤400 mg/dL OR

        -  HDL-cholesterol ≤50 mg/mL in women, ≤ 40mg/mL in men (with fasting triglycerides ≥110
           mg/dL).

      Each of the four recruiting centres will recruit 200 volunteers. Participants will be
      randomly assigned to one of four groups to receive either:

        -  Dairy BEF + egg placebo + bakery placebo

        -  Egg BEF + dairy placebo + bakery placebo

        -  Bakery BEF + dairy placebo + egg placebo

        -  Dairy, egg and bakery placebo

      Participants will be required to consume all three of the allocated products each day for 12
      weeks.

      Eligible volunteers will be included and randomly allocated to one of the four groups. At
      baseline, 6 weeks and 12 weeks after inclusion, each participant will visit the recruiting
      centre for clinical and biochemical investigations. At 3 weeks and 9 weeks participants will
      complete questionnaires relating to their satisfaction with the food products, compliance to
      consumption of the study food products, and any gastrointestinal side effects or
      health-related adverse events that have occurred in the previous 3 weeks.

      At each recruiting centre 40 participants will be required to take part in additional
      activities, these are: stool sample collection, adipose tissue aspiration, body composition
      analysis by dual energy x-ray absorptiometry (DEXA) and assessment of physical activity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Triglycerides blood levels (mg/dl)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in triglycerides blood levels after 12 weeks of consumption of foods enriched with DHA, alone or in combination with AC or BG, in subjects at risk for or affected by MS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL-cholesterol blood levels (mg/dl)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in HDL-cholesterol blood levels after 12 weeks of consumption of foods</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood glucose (mg/dl).</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in blood glucose levels after 12 weeks of consumption of foods enriched with DHA, alone or in combination with AC or BG, in subjects at risk for or affected by MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure (mmHg)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in blood pressure after 12 weeks of consumption of foods enriched with DHA, alone or in combination with AC or BG, in subjects at risk for or affected by MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference (cm).</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in waist circumference after 12 weeks of consumption of foods enriched with DHA, alone or in combination with AC or BG, in subjects at risk for or affected by MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary food metabolite levels (parts per millions).</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Changes from baseline in urinary food metabolite levels, after 12 weeks of consumption of foods enriched with DHA, alone or in combination with AC or BG, in subjects at risk for or affected by MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal microbiota composition (analysis of principal coordinates - PCOA)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Changes in fecal bacterial composition and diversity will be determined at baseline and after 12 weeks of consumption of foods enriched with DHA, alone or in combination with AC or BG, in subjects at risk for or affected by MS. The predominant microbial community and specific functional groups will be characterized by next-generation sequencing (NGS) of the 16S rDNA gene. The interindividual differences in the composition of the intestinal microbiota (beta-diversity) will be evaluated with the analysis of principal coordinates (PCOA). Appropriate statistical analysis will be performed to evaluate significant differences in the relative abundance of the microbial groups of intestinal microbiota between different groups of subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal Short Chain Fatty Acids (parts per million).</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in production/uptake in the stool of Short Chain Fatty Acids, after 12 weeks of consumption of foods enriched with DHA, alone or in combination with AC or BG, in subjects at risk for or affected by MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dna methylation levels (%).</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>To test whether lymphocytes may be useful as a surrogate for adipose tissue to detect changes in DNA methylation and gene expression, genome-wide methylation differences will be performed in parallel in lymphocytes and fat cells from baseline and after 12 weeks of consumption of foods enriched with DHA, alone or in combination with AC or BG, in subjects at risk for or affected by MS. Expression of affected genes will be evaluated by qRT-PCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Hemoglobin A1c (HbA1c) levels (%)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in HbA1c levels, after 12 weeks of consumption of foods enriched with DHA, alone or in combination with AC or BG, in subjects at risk for or affected by MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostasis Model Assessment (HOMA) Index levels.</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in Homeostasis Model Assessment Index levels, after 12 weeks of consumption of foods enriched with DHA, alone or in combination with AC or BG, in subjects at risk for or affected by MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal metabolite levels (parts per millions).</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in food metabolite levels in the stools after 12 weeks of consumption of foods enriched with DHA, alone or in combination with AC or BG, in subjects at risk for or affected by MS.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Dairy BEF + egg placebo + bakery placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 subjects consuming every day for 12 weeks: 1 portion of Dairy BEF + 1 portion of Egg placebo + 1 portion of Bakery placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Egg BEF + dairy placebo + bakery placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 subjects consuming every day for 12 weeks: 1 portion of Egg BEF + 1 portion of Dairy placebo + 1 portion of Bakery placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bakery BEF + dairy placebo + egg placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 subjects consuming every day for 12 weeks: 1 portion of Bakery BEF + 1 portion of Dairy placebo + 1 portion of Egg placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>All placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>200 subjects consuming every day for 12 weeks: 1 portion of Egg placebo + 1 portion of Dairy placebo + 1 portion of Bakery placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dairy BEF</intervention_name>
    <description>Dairy BEF: Milkshake powder enriched with 250 mg of DHA and 3g beta-glucans</description>
    <arm_group_label>Dairy BEF + egg placebo + bakery placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Egg BEF</intervention_name>
    <description>Egg BEF: Frozen pancakes enriched with 250 mg of DHA and 320 mg of anthocyanins</description>
    <arm_group_label>Egg BEF + dairy placebo + bakery placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bakery BEF</intervention_name>
    <description>Bakery BEF: Biscuits enriched with 250 mg of DHA and 320 mg of anthocyanins</description>
    <arm_group_label>Bakery BEF + dairy placebo + egg placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bakery placebo</intervention_name>
    <description>Bakery placebo: Biscuits without enrichment</description>
    <arm_group_label>Dairy BEF + egg placebo + bakery placebo</arm_group_label>
    <arm_group_label>Egg BEF + dairy placebo + bakery placebo</arm_group_label>
    <arm_group_label>All placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dairy placebo</intervention_name>
    <description>Dairy placebo: Milkshake powder without enrichment</description>
    <arm_group_label>Egg BEF + dairy placebo + bakery placebo</arm_group_label>
    <arm_group_label>Bakery BEF + dairy placebo + egg placebo</arm_group_label>
    <arm_group_label>All placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Egg placebo</intervention_name>
    <description>Egg placebo: Frozen pancakes without enrichment</description>
    <arm_group_label>Dairy BEF + egg placebo + bakery placebo</arm_group_label>
    <arm_group_label>Bakery BEF + dairy placebo + egg placebo</arm_group_label>
    <arm_group_label>All placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects presenting with two to four diagnostic criteria for metabolic syndrome, at
             least one of them being elevated fasting triglycerides OR HDL-cholesterol ≤50 mg/mL
             in women, ≤ 40mg/mL in men (with fasting triglycerides ≥110 mg/dL).

        Exclusion Criteria:

          -  subjects with five clinical criteria for metabolic syndrome

          -  Regular drug therapy with impact on serum lipids;

          -  Diabetes (fasting glucose &gt; 1.26 g/L, or anti-diabetic treatment);

          -  Celiac disease, lactose intolerance, allergy to milk or egg proteins;

          -  Antibiotic treatment within the last 3 months;

          -  Recent history of cancer or cancer treatment (less than 2 years);

          -  Active or recently diagnosed intestinal malabsorption;

          -  Diagnosis of organ failure

          -  Familial dyslipidemia (TG ≥ 4.5 mmol/l or 400 mg/dl);

          -  Illegal drug use or chronic alcoholism or smoking;

          -  Intensive physical exercise (≥ 5 hour/week);

          -  Consumption of nutritional supplements containing DHA, BG or AC;

          -  History of allergy or intolerance to any components used in BEF;

          -  Women who are pregnant or lactating;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandra Bordoni, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Agro-Food Sciences and Technologies, University of Bologna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luigi Ricciardiello, MD</last_name>
    <phone>+39 0516363381</phone>
    <email>luigi.ricciardiello@unibo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luigi Ricciardiello, MD</last_name>
    <phone>+39 0516363811</phone>
    <email>luigi.ricciardiello@unibo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de Récherche en Nutrition Humaine d'Auvergne</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Auvergne</state>
        <zip>63009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Ruddy, MD, PhD</last_name>
      <phone>+33 473608253</phone>
      <email>ruddy.richard@udamail.fr</email>
    </contact>
    <contact_backup>
      <last_name>Adeline Blot, Engineer</last_name>
      <phone>+33 473608253</phone>
      <email>adeline.blot@clermont.inra.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Nathalie Meunier, Engineer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Louis Sebedio, PhD, Dsc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Ruddy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adeline Blot, Engineer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Corinne Malpuech-Brugère, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier Dupont, Researcher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Max Rubner-Institut</name>
      <address>
        <city>Karlsruhe</city>
        <state>Baden-Württemberg</state>
        <zip>76131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Achim Bub, MD, PhD</last_name>
      <phone>+49 721 6625411</phone>
      <email>achim.bub@mri.bund.de</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Seifer</last_name>
      <phone>+49 721 6625411</phone>
      <email>tephanie.eifert@mri.bund.de</email>
    </contact_backup>
    <investigator>
      <last_name>Maria Herrmann</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernhard Watzl</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Bologna, Department of Medical and Surgical Sciences and Azienda Ospedaliero Universitaria di Bologna, Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Ricciardiello, MD</last_name>
      <phone>+393669614317</phone>
      <email>luigi.ricciardiello@unibo.it</email>
    </contact>
    <contact_backup>
      <last_name>Silvia Garelli, MD</last_name>
      <phone>+393284926634</phone>
      <email>silvia.garelli2@unibo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Luigi Ricciardiello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Garelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Prontera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisa Marcato, Dietitian</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Leeds</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9JT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Orfila, PhD, RNutr</last_name>
      <phone>+44 (0) 113 3432966</phone>
      <email>c.orfila@leeds.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Samantha Sutulic, PhD Fellow</last_name>
      <phone>+44 (0) 113 3430064</phone>
      <email>s.sutulic@leeds.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Caroline Orfila, PhD, RNutr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samantha Sutulic, PhD Fellow</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.pathway27.eu/</url>
    <description>Pathway-27 website</description>
  </link>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 31, 2016</lastchanged_date>
  <firstreceived_date>February 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</investigator_affiliation>
    <investigator_full_name>Luigi Ricciardiello</investigator_full_name>
    <investigator_title>Associate Professor of Gastroenterology, University of Bologna</investigator_title>
  </responsible_party>
  <keyword>bioactive</keyword>
  <keyword>enriched foods</keyword>
  <keyword>anthocyanins (AC)</keyword>
  <keyword>beta-glucans (BG)</keyword>
  <keyword>docosahexaenoic acid (DHA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual case report forms are available to collect study data into electronic form from all the recruiting centres. A central electronic database has been elaborated to capture, validate and manage the entered data by means of a variety of edit checks (e.g., subjecting the data to range checks, valid value checks, cross-checks, and manual review) that provide feedback to those entering/providing the data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
